Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/1999
10/26/1999US5972936 Benzofuran carboxamides and their therapeutic use
10/26/1999US5972935 Psychological disordrs, nervous system disorders, parkinson's disorder
10/26/1999US5972934 Stabilized nithiazine compositions
10/26/1999US5972933 Method of treating microbial infections
10/26/1999US5972932 Olanzapine or a salt or solvate thereof, and an opoid in a specific weight ratio; administering to provide mild pre-surgical anesthesia to provide amnesia while maintaining cooperation in mammals such as humans
10/26/1999US5972928 Administering an antigrowth agent
10/26/1999US5972927 Antiinflammatory, antiallergic and bronchodilatory medicinal products, treatment of asthma
10/26/1999US5972925 1-(3-(2-chloro-12h-dibenzo(d,g)(1,3,6)dioxazocin-12-yl)-1-prop yl)-3-piperidinecarboxylic acid, for example; treating neurogenic pain (in which c-fibers play a role) or inflammation such as migraine or diabetic neuropathy
10/26/1999US5972923 Methods and compositions to enhance the cytoprotective effects of polycyclic phenolic compounds through the synergistic interaction with anti-oxidants
10/26/1999US5972921 Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
10/26/1999US5972920 Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders
10/26/1999US5972919 Combination of a bronchodilator and a steroidal anti-inflammatory drug for the treatment of respiratory disorders, as well as its use and the preparation thereof
10/26/1999US5972917 Treatment and prophylaxis of hyperparathyroidism and hyperproliferative diseases, and in the modulation of the immune and inflammatory responses as well as the treatment of bone depletive disorders
10/26/1999US5972916 Treating migraine pain and the cluster of symptoms characteristic of migraine attack, such as nausea, photophobia, phonophobia and functional disabilities
10/26/1999US5972914 Remedies for liver diseases
10/26/1999US5972913 Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
10/26/1999US5972912 Dissolving an oxazaphosphorin in water, adding an amino acid to the solution to produce a mixture and lyophilizing the mixture to remove the water
10/26/1999US5972910 Reducing methane production in animals or improving the weight gain of an animal by administering an active materials enclosed in, confined or encapsulated with cyclodextrins
10/26/1999US5972909 Removal wastes
10/26/1999US5972907 Synthetic core 2-like branched structures containing GalNAc-lewisx and Neu5Acα2-3Galβ1-3GalNAc sequences as novel ligands for selectins
10/26/1999US5972906 Administering topically an effective amount of antiinflammatory agent/non-steroid/ and a form of hyaluronic acid selected from hyaluronic acid or salts
10/26/1999US5972905 Use of oligosaccharides for the treatment of pruritus cutaneus associated with renal failure
10/26/1999US5972904 Method of treating sinusitis with uridine triphosphates and related compounds
10/26/1999US5972901 Making a composition for delivering an oligonucleotide to a mammalian cell by providing a peptide target binding moiety being capable of binding to a serpin enzyme complex receptor, polylysine, an oligonucleotide vector; conjugating, coupling
10/26/1999US5972900 Conjugating target binding moiety consisting of an antibody or fragment which binds to secretory component of polymeric immunoglobulin receptor on surface of epithelium cell, nucleic acid binder, expression vector, compacting, administering
10/26/1999US5972898 Erythromycin a derivatives as lutenizing hormone releasing hormone (lhrh) antagonists, and methods of their preparation
10/26/1999US5972897 Acylated enol derivatives as prodrugs of elastase inhibitors
10/26/1999US5972892 For reducing or eliminating the skin irritant side-effect of a therapeutic composition; a stabilizer for desensitization
10/26/1999US5972881 Treating NIDDM with RXR agonists
10/26/1999US5972879 Inhibiting agent against the proliferation of tumor cells
10/26/1999US5972676 Diagnosis and treatment of AUR-1 and/or AUR-2 related disorders
10/26/1999US5972664 Methods and compositions for synthesis of long chain poly-unsaturated fatty acids
10/26/1999US5972652 Polynucleotides encoding secreted proteins
10/26/1999US5972651 Polynucleotides and polypeptides of the fifty-four homologue family, (ffh); vectors and transformed host cells; ffh are components of protein secretory apparatus and their inhibition of function is deleterious to bacteria cells
10/26/1999US5972650 Can be used as vehicles for the delivery of nucleic acids that can serve as therapeutic agents and as part of vaccines designed to immunize people or animals against viral diseases.
10/26/1999US5972606 A polypeptide; treating osteoporosis, eating disorders, brain disorders, adult respiratory disease syndrome, huntington'sdisease, ulcers, cardiovascular disorders, parkinson's disease;
10/26/1999US5972599 High affinity nucleic acid ligands of cytokines
10/26/1999US5972598 Methods for preventing multidrug resistance in cancer cells
10/26/1999US5972593 Method for the photo-decontamination of pathogens in blood using 4'-primary amino psoralens
10/26/1999US5972383 Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
10/26/1999US5972381 Solid solution of an antifungal agent with enhanced bioavailability
10/26/1999US5972379 Liposomes having a surface coating of hydrophilic polymer chains and an entrapped ciprofloxacin-amino acid conjugate, useful for treating the bacterial infections
10/26/1999US5972377 Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen
10/26/1999US5972369 Includes reservoir comprising beneficial agent and capillary channel in communication with reservoir and exterior of system for delivering beneficial agent from system
10/26/1999US5972367 A sugar, amino acids, electrolytes and a fat emulsion for nutrient supply use.
10/26/1999US5972358 A hydroalcohol detackifying mixture consist of stearoxy trimethylsilane, cetyl lactate, cyclomethicone, c12-c15 alkyl lactate and alcohol selected from ethanol, propanol, isopropanol and water; topical skin care products
10/26/1999US5972355 Stable water-containing cosmetic or pharmaceutical compositions which comprise biologically active agent and enzyme-based oxygen-scavenging antioxidant system
10/26/1999US5972350 Prevention and treatment of chlamydia diseases in cats
10/26/1999US5972349 Synthesis of polyribosylribitol phosphate oligosaccharides
10/26/1999US5972345 Comprising saw palmetto extract, african pygeum extract, stinging nettle extract
10/26/1999US5972342 Antidiabetic agents
10/26/1999US5972337 46 kilodalton human milk fat globule (HMFG) antigen, fragments and fusion protein
10/26/1999US5972329 Fixative polymers
10/26/1999US5972328 Inhibiting amyloid deposition by administering glycerol trisulfuric acid or pharmaceutically acceptable salt
10/26/1999US5972327 Topically manually applying a composition in the form of an ointment or creme containing an anti-allergic rhinitis effective amount of a medical agent selected from the group consisting of steroids, antihistamines and anti-cholinergics
10/26/1999US5972326 Controlled release of pharmaceuticals in the anterior chamber of the eye
10/26/1999US5972324 Dimeric urethane compounds derived from monohydric alcohols, generally fatty alcohols, and a diisocyanate.
10/26/1999US5972320 Antiperspirant or deodorant composition with silicone latex
10/26/1999US5972317 Nail-permeable medication means is disclosed for delivering a medicament through nails, claws, hoofs, or other similar hardened tissue of dermal derivation; includes proteolytic enzyme and drug selected to treat specific disease
10/26/1999US5972309 Identification of an exogenous intra-erythrocytic bacterium in patients having systemic lupus erythematosus, and treatment
10/26/1999CA2183320C Novel mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase and ace
10/26/1999CA2177576C Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
10/26/1999CA2163118C Aurintricaboxylic acid fractions and analogues with anti-angiogenic activity and methods of use
10/26/1999CA2132993C Physiologically active substance
10/26/1999CA1340804C Mixed compositions for treating hypercholesterolemia
10/26/1999CA1340801C Optically active pyridonecarboxylic acid derivatives
10/26/1999CA1340798C Disubstituted pyridines
10/21/1999WO1999053076A1 Tao protein kinases and methods of use therefor
10/21/1999WO1999053039A1 Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily
10/21/1999WO1999053020A1 6-phosphogluconate dehydrogenase of streptococcus pneumoniae
10/21/1999WO1999052938A2 Identification of chemical active agents for inhibiting the 1-desoxy-d-xylulose-5-phosphate biosynthetic pathway in parasites
10/21/1999WO1999052936A2 Arginine peptide analogs useful as fibroblast growth factor antagonists
10/21/1999WO1999052935A1 Crystalline forms of 1s-[1alpha (2s*,3r*), 9alpha]-6, 10-dioxo-n- (2-ethoxy-5 -oxo-tetrahydro-3 -furanyl) -9-[[(1-isoquinolyl) carbonyl]-amino] octahydro-6h -piridazino[1, 2-a][1,2] diazepin- 1-carboxamide
10/21/1999WO1999052932A1 Fatty acid derivatives of bile acids and bile acid derivatives
10/21/1999WO1999052931A1 Solid dispersion containing sialic acid derivative
10/21/1999WO1999052929A1 Nucleic acid sequences and proteins associated with aging
10/21/1999WO1999052927A1 Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
10/21/1999WO1999052925A1 Programmed cell death and caspase-12
10/21/1999WO1999052921A1 13-dihydro-3'aziridino anthracyclines
10/21/1999WO1999052910A1 Bicyclic hydroxamic acid derivatives
10/21/1999WO1999052907A1 Azabicyclic 5ht1 receptor ligands
10/21/1999WO1999052903A1 Prodrugs of benzofuranylmethyl carbamate nk1 antagonists
10/21/1999WO1999052902A1 Method for drying anhydrous paroxetine hydrochloride
10/21/1999WO1999052901A1 Paroxetine maleate
10/21/1999WO1999052898A1 N,n-disubstituted amides that inhibit the binding of integrins to their receptors
10/21/1999WO1999052896A1 Heterocyclic glycyl beta-alanine derivatives as vitronectin antagonists
10/21/1999WO1999052895A1 Amidine compounds
10/21/1999WO1999052890A1 Chromanone and thiochromanone derivatives
10/21/1999WO1999052889A1 (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides
10/21/1999WO1999052887A1 7-hexanoyltaxol and methods for preparing the same
10/21/1999WO1999052879A1 Acylresorcinol derivatives as selective vitronectin receptor inhibitors
10/21/1999WO1999052877A1 Receptor ligands
10/21/1999WO1999052876A1 Azacycloalkane derivatives, preparation and therapeutic application
10/21/1999WO1999052870A1 4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists
10/21/1999WO1999052869A1 Substituted indolinones having an inhibiting effect on kinases and cycline/cdk complexes
10/21/1999WO1999052868A1 Substituted pyrrolidine hydroxamate metalloprotease inhibitors
10/21/1999WO1999052863A1 VITAMIN D DERIVATIVES SUBSTITUTED AT THE 2β-POSITION
10/21/1999WO1999052862A1 Process for alkylating hindered sulfonamides useful in the production of matrix metalloproteinase inhibitors
10/21/1999WO1999052858A2 Lipids
10/21/1999WO1999052848A1 Phosphodiesterase isoenzyme denominated 4 (pde 4) inhibiting compounds
1 ... 6424 6425 6426 6427 6428 6429 6430 6431 6432 6433 6434 6435 6436 6437 6438 6439 6440 6441 6442 6443 6444 ... 7860